89bio Inc (ETNB) concluded trading on Thursday at a closing price of $8.96, with 3.86 million shares of worth about $34.58 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 18.36% during that period and on March 27, 2025 the price saw a gain of about 11.72%. Currently the company’s common shares owned by public are about 145.98M shares, out of which, 140.33M shares are available for trading.
Stock saw a price change of 2.63% in past 5 days and over the past one month there was a price change of -2.71%. Year-to-date (YTD), ETNB shares are showing a performance of 14.58% which decreased to -20.99% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.99 but also hit the highest price of $11.84 during that period. The average intraday trading volume for 89bio Inc shares is 2.36 million. The stock is currently trading 6.34% above its 20-day simple moving average (SMA20), while that difference is down -0.81% for SMA50 and it goes to 5.92% higher than SMA200.
89bio Inc (NASDAQ: ETNB) currently have 145.98M outstanding shares and institutions hold larger chunk of about 89.70% of that.
The stock has a current market capitalization of $1.31B and its 3Y-monthly beta is at 1.25. It has posted earnings per share of -$3.43 in the same period. It has Quick Ratio of 13.19 while making debt-to-equity ratio of 0.09. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ETNB, volatility over the week remained 11.46% while standing at 8.26% over the month.
Stock’s fiscal year EPS is expected to rise by 40.20% while it is estimated to decrease by -0.87% in next year. EPS is likely to shrink at an annualized rate of 17.78% for next 5-years, compared to annual growth of 32.21% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on March 14, 2025 offering a Neutral rating for the stock and assigned a target price of $11 to it. Coverage by Citigroup stated 89bio Inc (ETNB) stock as a Buy in their note to investors on March 13, 2025, suggesting a price target of $25 for the stock. On February 04, 2025, Wolfe Research Initiated their recommendations, while on April 22, 2024, BofA Securities Resumed their ratings for the stock with a price target of $30. Stock get a Sector perform rating from RBC Capital Mkts on January 12, 2024.
